Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia

KS Baker(University of Minnesota), BR Blazar(University of Minnesota Medical Center), Bruce Bostrom(Minnesota West Community & Technical College), Todd E. DeFor(NHS Blood and Transplant), WG Woods(University of Minnesota Medical Center), NKC Ramsay(University of Minnesota)
Bone Marrow Transplantation
September 1, 2000
10.1038/sj.bmt.1702590
Cited by 30

Related Papers

A randomized comparison of nativeEscherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study
|Blood|2002|496
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
|Blood|2018|406
Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group
|Blood|2003|361
Comparison of Autologous and Allogeneic Bone Marrow Transplantation for Treatment of High-Risk Refractory Acute Lymphoblastic Leukemia
|New England Journal of Medicine|1987|334
Juvenile xanthogranuloma: Forms of systemic disease and their clinical implications
|The Journal of Pediatrics|1996|294